alpha-adrenergic receptor antagonist

This page covers all alpha-adrenergic receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting alpha-adrenergic receptor.

Targets

alpha-adrenergic receptor

Phase 3 pipeline (1)

• Phentolamine Mesylate (NV-101) · Novalar Pharmaceuticals, Inc. · Cardiovascular
  Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict.

Patent intelligence

• alpha adrenergic receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates